nContact Surgical Inc. is now nContact Inc.
The Morrisville, N.C.-based cardiac device manufacturer said its new name represents a move towards less invasive, endoscopic approaches for treating irregular heartbeat with epicardial ablation. The company’s surgical tools allow cardiologists to treat arrhythmias through a small midline abdominal incision, according to the company.
“By removing ‘Surgical’ from our company name, we are categorically affirming our mission to transform the ablation market and change the dialogue from individual surgical or catheter approaches to interdisciplinary and [epicardial]-only approaches that may achieve greater scientific and clinical endpoints,” CEO John Funkhouser said in prepared remarks.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In November, nContact raised $16 million in a Series D round to support its endoscopic cardiac ablation system for treating atrial fibrillation.
Related articles
- Atricure enrolls first patient in atrial fibrillation clinical trial (medcitynews.com)
- FDA approves Medtronic’s Artic Front therapy for irregular heartbeats (medcitynews.com)
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
